57338-20-2

Upstream product

• 100-01-6 4-nitro-aniline 
• 94-05-3 2-cyano-3-ethoxyacrylic acid ethyl ester 
• 77755-81-8 N-(2-morpholinoethyl)-4-nitroaniline 

Downstream Products

• 2305-65-9 4-hydroxy-6-nitroquinoline-3-carbonitrile 
• 214470-35-6 6-nitro-4-oxo-1,4-dihydro-quinoline-3-carbonitrile 
• 214485-09-3 4-[(3-chloro-4-fluorophenyl)amino]-6-nitro-quinoline-3-carbonitrile 
• 214485-08-2 6-Amino-4-[(3-chloro-4-fluorophenyl)amino]-quinoline-3-carbonitrile 
• 214470-37-8 4-chloro-6-nitro-3-quinolinecarbonitrile 
• 915360-45-1 6-(3-amino-benzylamino)-4-(3-chloro-4-fluoro-phenylamino)-quinoline-3-carbonitrile 

Relevant academic research and scientific papers

Identification of a novel class of selective Tpl2 kinase inhibitors: 4-Alkylamino-[1,7]naphthyridine-3-carbonitriles

We have previously reported the discovery and initial SAR of the [1,7]naphthyridine-3-carbonitriles and quinoline-3-carbonitriles as Tumor Progression Loci-2 (Tpl2) kinase inhibitors. In this paper, we report new SAR efforts which have led to the identifi

Inhibition of Tpl2 kinase and TNFα production with quinoline-3-carbonitriles for the treatment of rheumatoid arthritis

The synthesis and structure-activity studies of a series of quinoline-3-carbonitriles as inhibitors of Tpl2 kinase are described. Potent inhibitors of Tpl2 kinase with selectivity against a panel of selected kinases in enzymatic assays and specificity in cell-based phosphorylation assays in LPS-treated human monocytes were identified. Selected inhibitors with moderate activity in human whole blood assay effectively inhibited LPS/D-Gal induced TNFα release when administered intraperitoneally in mice.

USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS

This invention provides a method of treating or inhibiting colonic polyps which comprises providing a compound of formula (1); wherein R1, R2, R3, R4, X, Y, and n are defined hereinbefore, or a pharmaceutically acceptable salt thereof.

SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS

This invention provides compounds of formula (1) wherein R1, G1, G2, R4, Z, X and n are defined herein, or a pharmaceutically acceptable salt thereof, which are useful as antineoplastic agents and in the treatment of polycystic kidney disease.

Method of treating or inhibiting colonic polyps

This invention provides a method of treating or inhibiting colonic polyps which comprises providing a compound of formula 1 wherein:R1, R2, R3, R4, X, Y, and n are as defined hereinbefore, or a pharmaceutically acceptable salt thereof.

Substituted 3-cyanoquinolines

This invention provides compounds of formula I having the structure wherein G1, G2, R1, R4, Z, n, and X are defined in the specification or a pharmaceutically acceptable salt thereof which are useful as antineoplastic agents and in the treatment of polycystic kidney disease.